Avoro Capital Advisors LLC historic quarter change: USA Other Stocks, New
In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 17 quarters from 2014-12-31 to 2026-06-30, Avoro Capital Advisors LLC opened 45 positions, added to 51, reduced 48 and sold out of 43.
- Q1 2026: Stock DAMORA THERAPEUTICS INC; Country of operation —; Class Common; Shares before 0.
- Q4 2024: Stock BLUEPRINT MEDICINES CORP; Country of operation United States; Class Common; Shares before 0.
- Q1 2024: Stock ALPINE IMMUNE SCIENCES INC; Country of operation United States; Class Common; Shares before 0.
- Q3 2016: Stock AERIE PHARMACEUTICALS INC; Country of operation —; Class Common; Shares before 0.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1633313), 17 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-03-16); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-13); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2014-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q1 2026 | DAMORA THERAPEUTICS INC
CUSIP 36322Q206 | | Common | 0 | 3,783,000 | +3,783,000 | $0 | $97,979,700 | +$97,979,700 | 2026-05-15 |
|---|
| Q4 2024 | BLUEPRINT MEDICINES CORP
CUSIP 09627Y109 | United States | Common | 0 | 1,185,000 | +1,185,000 | $0 | $103,355,700 | +$103,355,700 | 2025-02-14 |
|---|
| Q1 2024 | ALPINE IMMUNE SCIENCES INC
CUSIP 02083G100 | United States | Common | 0 | 5,775,000 | +5,775,000 | $0 | $228,921,000 | +$228,921,000 | 2024-05-15 |
|---|
| Q3 2016 | AERIE PHARMACEUTICALS INC
CUSIP 00771V108 | | Common | 0 | 500,000 | +500,000 | $0 | $18,870,000 | +$18,870,000 | 2016-11-14 |
|---|
| Q3 2016 | SEATTLE GENETICS INC
CUSIP 812578102 | | Common | 0 | 141,500 | +141,500 | $0 | $7,642,000 | +$7,642,000 | 2016-11-14 |
|---|
| Q3 2016 | ALIMERA SCIENCES INC
CUSIP 016259103 | | Common | 0 | 3,575,000 | +3,575,000 | $0 | $5,327,000 | +$5,327,000 | 2016-11-14 |
|---|
| Q3 2016 | PROTEOSTASIS THERAPEUTICS INC
CUSIP 74373B109 | | Common | 0 | 179,565 | +179,565 | $0 | $2,799,000 | +$2,799,000 | 2016-11-14 |
|---|
| Q3 2016 | VERSARTIS INC
CUSIP 92529L102 | | Common | 0 | 95,742 | +95,742 | $0 | $1,173,000 | +$1,173,000 | 2016-11-14 |
|---|
| Q3 2016 | ONCOMED PHARMACEUTICALS INC
CUSIP 68234X102 | | Common | 0 | 85,000 | +85,000 | $0 | $972,000 | +$972,000 | 2016-11-14 |
|---|
| Q3 2016 | CEMPRA INC
CUSIP 15130J109 | | Common | 0 | 30,000 | +30,000 | $0 | $726,000 | +$726,000 | 2016-11-14 |
|---|
| Q3 2016 | DICERNA PHARMACEUTICALS INC
CUSIP 253031108 | | Common | 0 | 46,082 | +46,082 | $0 | $271,000 | +$271,000 | 2016-11-14 |
|---|
| Q2 2016 | RELYPSA INC
CUSIP 759531106 | | Common | 0 | 613,300 | +613,300 | $0 | $11,346,000 | +$11,346,000 | 2016-08-15 |
|---|
| Q2 2016 | CASCADIAN THERAPEUTICS INC
CUSIP 14740B101 | | Common | 0 | 5,744,723 | +5,744,723 | $0 | $5,418,000 | +$5,418,000 | 2016-08-15 |
|---|
| Q2 2016 | ONCOBIOLOGICS INC
CUSIP 68235M105 | | Common | 0 | 466,667 | +466,667 | $0 | $1,587,000 | +$1,587,000 | 2016-08-15 |
|---|
| Q2 2016 | ASSEMBLY BIOSCIENCES INC
CUSIP 045396108 | | Common | 0 | 260,982 | +260,982 | $0 | $1,448,000 | +$1,448,000 | 2016-08-15 |
|---|
| Q1 2016 | MEDIVATION INC
CUSIP 58501N101 | | Common | 0 | 270,665 | +270,665 | $0 | $12,445,000 | +$12,445,000 | 2016-05-16 |
|---|
| Q1 2016 | ANACOR PHARMACEUTICALS INC
CUSIP 032420101 | | Common | 0 | 166,700 | +166,700 | $0 | $8,910,000 | +$8,910,000 | 2016-05-16 |
|---|
| Q1 2016 | TESARO INC.
CUSIP 881569107 | | Common | 0 | 150,000 | +150,000 | $0 | $6,605,000 | +$6,605,000 | 2016-05-16 |
|---|
| Q1 2016 | GLOBAL BLOOD THERAPEEUTICS INC
CUSIP 37890U108 | | Common | 0 | 208,086 | +208,086 | $0 | $3,300,000 | +$3,300,000 | 2016-05-16 |
|---|
| Q1 2016 | IMMUNOMEDICS INC
CUSIP 452907108 | | Common | 0 | 1,050,457 | +1,050,457 | $0 | $2,626,000 | +$2,626,000 | 2016-05-16 |
|---|
| Q4 2015 | TELIGENT INC.
CUSIP 87960W104 | | Common | 0 | 1,373,294 | +1,373,294 | $0 | $12,222,000 | +$12,222,000 | 2016-02-12 |
|---|
| Q4 2015 | ACCELERATE DIAGNOSTICS, INC.
CUSIP 00430H102 | | Common | 0 | 112,885 | +112,885 | $0 | $2,426,000 | +$2,426,000 | 2016-02-12 |
|---|
| Q3 2015 | AEGERION PHARMACEUTICALS INC
CUSIP 00767E102 | | Common | 0 | 806,300 | +806,300 | $0 | $10,966,000 | +$10,966,000 | 2015-11-13 |
|---|
| Q3 2015 | DERMIRA INC
CUSIP 24983L104 | | Common | 0 | 363,250 | +363,250 | $0 | $8,478,000 | +$8,478,000 | 2015-11-13 |
|---|
| Q3 2015 | SPECTRUM PHARMACEUTICALS INC
CUSIP 84763A108 | | Common | 0 | 1,315,600 | +1,315,600 | $0 | $7,867,000 | +$7,867,000 | 2015-11-13 |
|---|
| Q3 2015 | NANTKWEST- INC
CUSIP 63016Q102 | | Common | 0 | 728,887 | +728,887 | $0 | $7,301,000 | +$7,301,000 | 2015-11-13 |
|---|
| Q3 2015 | EGALET CORPORATION.
CUSIP 28226B104 | | Common | 0 | 440,606 | +440,606 | $0 | $5,807,000 | +$5,807,000 | 2015-11-13 |
|---|
| Q3 2015 | CATALYST BIOSCIENCES INC.
CUSIP 14888D109 | | Common | 0 | 83,901 | +83,901 | $0 | $391,000 | +$391,000 | 2015-11-13 |
|---|
| Q2 2015 | CELLDEX THERAPEUTICS INC
CUSIP 15117B103 | | Common | 0 | 352,350 | +352,350 | $0 | $8,886,000 | +$8,886,000 | 2015-08-14 |
|---|
| Q2 2015 | AXOVANT SCIENCES LTD.
CUSIP G0750W104 | | Common | 0 | 340,000 | +340,000 | $0 | $6,929,000 | +$6,929,000 | 2015-08-14 |
|---|
| Q2 2015 | NEURODERM LTD.
CUSIP M74231107 | | Common | 0 | 371,111 | +371,111 | $0 | $5,697,000 | +$5,697,000 | 2015-08-14 |
|---|
| Q2 2015 | ALLIQUA BIOMEDICAL INC
CUSIP 019621200 | | Common | 0 | 800,000 | +800,000 | $0 | $4,216,000 | +$4,216,000 | 2015-08-14 |
|---|
| Q2 2015 | FORTRESS BIOTECH INC.
CUSIP 34960Q109 | United States | Common | 0 | 929,531 | +929,531 | $0 | $3,123,000 | +$3,123,000 | 2015-08-14 |
|---|
| Q1 2015 | LION BIOTECHNOLOGIES INC
CUSIP 53619R102 | | Common | 0 | 2,149,907 | +2,149,907 | $0 | $26,035,000 | +$26,035,000 | 2015-05-15 |
|---|
| Q1 2015 | CELGENE CORP.
CUSIP 151020904 | | Common | 0 | 148,800 | +148,800 | $0 | $17,154,000 | +$17,154,000 | 2015-05-15 |
|---|
| Q1 2015 | MIRATI THERAPEUTICS INC.
CUSIP 60468T105 | United States | Common | 0 | 320,867 | +320,867 | $0 | $9,408,000 | +$9,408,000 | 2015-05-15 |
|---|
| Q1 2015 | STEMLINE THERAPEUTICS - INC
CUSIP 85858C107 | | Common | 0 | 475,000 | +475,000 | $0 | $6,873,000 | +$6,873,000 | 2015-05-15 |
|---|
| Q1 2015 | TONIX PHARMACEUTICALS HLDG
CUSIP 890260201 | | Common | 0 | 755,300 | +755,300 | $0 | $4,773,000 | +$4,773,000 | 2015-05-15 |
|---|
| Q1 2015 | TRILLIUM THERAPEUTICS INC
CUSIP 89620X506 | | Common | 0 | 160,697 | +160,697 | $0 | $3,234,000 | +$3,234,000 | 2015-05-15 |
|---|
| Q1 2015 | CHEMOCENTRYX - INC
CUSIP 16383L106 | | Common | 0 | 323,607 | +323,607 | $0 | $2,443,000 | +$2,443,000 | 2015-05-15 |
|---|
| Q1 2015 | THERAPEUTICS MD INC
CUSIP 88338N107 | | Common | 0 | 392,000 | +392,000 | $0 | $2,372,000 | +$2,372,000 | 2015-05-15 |
|---|
| Q1 2015 | CORONADO BIOSCIENCES INC
CUSIP 21976U109 | | Common | 0 | 600,000 | +600,000 | $0 | $2,310,000 | +$2,310,000 | 2015-05-15 |
|---|
| Q1 2015 | TROVAGENE INC
CUSIP 897238309 | | Common | 0 | 323,728 | +323,728 | $0 | $2,205,000 | +$2,205,000 | 2015-05-15 |
|---|
| Q1 2015 | HEAT BIOLOGICS INC
CUSIP 42237K102 | | Common | 0 | 260,000 | +260,000 | $0 | $1,654,000 | +$1,654,000 | 2015-05-15 |
|---|
| Q1 2015 | TARGACEPT INC
CUSIP 87611R306 | | Common | 0 | 466,297 | +466,297 | $0 | $1,385,000 | +$1,385,000 | 2015-05-15 |
|---|